Bian Wu

Dr. Bian Wu

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
YZYongqiang Zheng
Yongqiang Zheng
YCYing Chen
Ying Chen
KYKaixu Yu
Kaixu Yu
YYYun Yang
Yun Yang
XWXindi Wang
Xindi Wang
BWBian Wu
Bian Wu
Introduction Cancer patients are prone to infections, but the mortality of fatal infections remains unclear. Understanding the patterns of fatal infections in patients with cancer is imperative. In this study, we report the characteristics, incidence, and predictive risk factors of fatal infections among a population-based cancer cohort. Methods A total of 8,471,051 patients diagnosed with cancer between 1975 and 2016 were retrospectively identified from the Surveillance, Epidemiology, and End Results (SEER) program. The primary outcome was dying from fatal infections. Mortality rates and standardized mortality ratios (SMRs) adjusted for age, sex, race, and calendar year were calculated to characterize the relative risks of dying from fatal infections and to compare with the general population. Furthermore, cumulative mortality rates and the Cox regression models were applied to identify predictive risk factors of fatal infections. Results In cancer patients, the mortality rate of fatal infections was 260.1/100,000 person-years, nearly three times that of the general population [SMR, 2.92; 95% (confidence interval) CI 2.91–2.94]. Notably, a decreasing trend in mortality rate of fatal infections was observed in recent decades. SMRs of fatal infections were highest in Kaposi sarcoma (SMR, 162.2; 95% CI 159.4–165.1), liver cancer (SMR, 30.9; 95% CI 30.0–31.8), acute lymphocytic leukemia (SMR, 19.1; 95% CI 17.0–21.4), and acute myeloid leukemia (SMR, 13.3; 95% CI 12.4–14.3). Patients aged between 20 and 39 years old exhibited a higher cumulative mortality rate in the first few years after cancer diagnosis, whereas the cumulative mortality rate of those > 80 years old was rapidly increasing and became the highest approximately 3 years post-cancer diagnosis. Predictive risk factors of dying from fatal infections in cancer patients were the age of 20–39 or > 80 years, male sex, black race, diagnosed with cancer before 2000, unmarried status, advanced cancer stage, and not receiving surgery and radiotherapy, but receiving chemotherapy. Conclusion Cancer patients were at high risks of dying from infectious diseases. Certain groups of cancer patients, including those aged between 20 and 39 or > 80 years, as well as those receiving chemotherapy, should be sensitized to the risk of fatal infections.

2 August 2017 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
BWBian Wu
Bian Wu
MSMikołaj Słabicki
Mikołaj Słabicki
LSLeopold Sellner
Leopold Sellner
SDSascha Dietrich
Sascha Dietrich
XLXiyang Liu
Xiyang Liu
TZThorsten Zenz
Thorsten Zenz

5 February 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
KYKunyu Yang
Kunyu Yang
YZYongqiang Zheng
Yongqiang Zheng
JPJiangtong Peng
Jiangtong Peng
JCJiayuan Chen
Jiayuan Chen
HFHuayi Feng
Huayi Feng
BWBian Wu
Bian Wu
Injury is an important cause of death among patients with cancer.1 An increased risk of self-inflicted injury, mainly suicide, has been observed among patients with cancer compared with the general population.2,3 Unintentional injuries, another major category of injury, are the third-leading causes of death in the United States.4 There is evidence5,6 to suggest that suicide and death from unintentional injury share similar risk factors, such as mental distress, physical illnesses, and impaired social and physical functioning caused by treatment. Thus, we believe that it is necessary to examine not only suicide but also death due to unintentional injury among patients with cancer. Few studies7-9 have identified increased risk of death from unintentional injury among patients with cancer. Camidge et al7 found a relative risk of 1.58 for death from unintentional injury among patients with cancer compared with the general Scottish population. In Japan, Yamauchi et al8 reported a relative risk for externally caused injury of 18.8 within the first year after cancer diagnosis. However, no large studies, to our knowledge, have examined the rates of death due to unintentional injury among patients with cancer, and it remains unclear which patient and disease characteristics, such as anatomic site of cancer, are associated with higher rates of death from unintentional injury.

23 December 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MLMengting Li
Mengting Li
FTFan Tong
Fan Tong
BWBian Wu
Bian Wu
XDXiaorong Dong
Xiaorong Dong
Radiation therapy is widely recognized as an efficacious modality for treating neoplasms located within the craniofacial region. Nevertheless, this approach is not devoid of risks, predominantly concerning potential harm to the neural structures. Adverse effects may encompass focal cerebral necrosis, cognitive function compromise, cerebrovascular pathology, spinal cord injury, and detriment to the neural fibers constituting the brachial plexus. With increasing survival rates among oncology patients, evaluating post-treatment quality of life has become crucial in assessing the benefits of radiation therapy. Consequently, it is imperative to investigate therapeutic strategies to mitigate cerebral complications from radiation exposure. Current management of radiation-induced cerebral damage involves corticosteroids and bevacizumab, with preclinical research on antioxidants and thalidomide. Despite these efforts, an optimal treatment remains elusive. Recent studies suggest the gut microbiota’s involvement in neurologic pathologies. This review aims to discuss the causes and existing treatments for radiation-induced cerebral injury and explore gut microbiota modulation as a potential therapeutic strategy.

27 August 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PYPengcheng Yang
Pengcheng Yang
YZYongqiang Zheng
Yongqiang Zheng
JCJiayuan Chen
Jiayuan Chen
HMHaotian Ma
Haotian Ma
KYKaixu Yu
Kaixu Yu
BWBian Wu
Bian Wu
Background: Receiving a cancer diagnosis may trigger immediate fatal non-cancer health outcomes in addition to dying of cancer itself. We aim to investigate the full pattern of non-cancer deaths in patients within a year of a cancer diagnosis.Methods: Patients diagnosed with cancer between 1990 and 2016 were identified from the SEER program. Standardized mortality ratios (SMRs) were calculated to characterize the relative risks of non-cancer deaths compared with the general population.Results: Among 7,366,229 patients, 241,575 non-cancer deaths (15.9%) were recorded in the first year following a cancer diagnosis. The relative risk of non-cancer deaths was 2.34-fold (95% confidence interval (CI): 2.33–2.35) that of the general population. The majority of non-cancer deaths were caused by cardiovascular diseases (21.8%), followed by infectious diseases (7.2%). Significant elevations in mortality risks were observed for nearly all non-cancer causes, particularly in infectious diseases (SMR: 5.08; 95% CI: 5.03–5.13). Patients with liver cancer (SMR: 12.29; 95% CI: 12.06–12.53) were at the highest risk of early non-cancer deaths. The risks of non-cancer deaths were highest within the first month after diagnosis, and decreased rapidly thereafter.Conclusions: Risks of non-cancer deaths vary by the types of causes and anatomic sites of cancer. Our data underscore the importance of close observation and early multidisciplinary care for noncancer conditions in patients who have recently received a cancer diagnosis.

27 April 2021 in Aging
Verified
Journal Article
Open access
YZYongqiang Zheng
Yongqiang Zheng
YHYan Huang
Yan Huang
XZXiwen Zheng
Xiwen Zheng
JPJiangtong Peng
Jiangtong Peng
YCYing Chen
Ying Chen
BWBian Wu
Bian Wu
Features of the deaths caused by COPD (chronic obstructive pulmonary disease) in cancer patients remained a controversial issue. This study aimed to characterize the demographic characteristics and mortality rates of the deaths from COPD in patients with cancer. In total, 7,846,370 cancer patients aged 40 years or older in the United States were identified from the Surveillance, Epidemiology, and End Results database (1975-2016). Mortality rates and SMRs (standardized mortality ratios) adjusted by age, race, sex, and calendar year were calculated to investigate the risk of COPD deaths in cancer survivors and to compare it with the general population. A total of 119,228 COPD deaths in patients with cancer were recorded, with a mortality rate of 261.5/100,000 person-years, nearly two-fold that of the general population (SMR, 2.17; 95% CI [confidence interval], 2.16-2.18). The proportion of cancer survivors dying from COPD increased from 0.9% in 1975 to 3.4% in 2016. Patients with lung cancer had a higher overall risk (SMR, 9.23; 95% CI, 9.12-9.35) than those with extrapulmonary malignancies. Among all extrapulmonary sites, laryngeal (SMR, 5.54; 95% CI, 5.34-5.75) and esophageal cancers (SMR, 4.33; 95% CI, 4.04-4.63) had the highest SMR. The risk of death from COPD increased with follow-up time.